En langsigtet opfølgningsundersøgelse af forsøgspersoner, der modtog CRISPR CAR T-celleterapi
En langsigtet opfølgningsundersøgelse af forsøgspersoner med maligniteter behandlet med CRISPR CAR T celleterapi
This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. Subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this LTFU study. This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
-
Melbourne, Australien
- Alfred Health
-
Nedlands, Australien, 6009
- Sir Charles Gairdner
-
Richmond, Australien
- Epworth Healthcare
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- Royal Prince Alfred Hospital
-
-
Victoria
-
Melbourne, Victoria, Australien, 3000
- Peter MacCallum Cancer Center
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret
-
-
-
-
California
-
Duarte, California, Forenede Stater, 91010
- City of Hope
-
Los Angeles, California, Forenede Stater, 90048
- Cedars Sinai
-
Stanford, California, Forenede Stater, 94305
- Stanford
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06510
- Yale New Haven Hospital
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Emory
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- University of Chicago
-
-
Kansas
-
Westwood, Kansas, Forenede Stater, 66205
- University of Kansas
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455
- University of Minnesota
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University Saint Louis
-
-
New York
-
New York, New York, Forenede Stater, 10065
- MSKCC
-
The Bronx, New York, Forenede Stater, 10467
- Montefiore Medical Center
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- University of Pennsylvania
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75390
- UT Southwestern
-
Houston, Texas, Forenede Stater, 77030
- MD Anderson Cancer Center
-
San Antonio, Texas, Forenede Stater, 78229
- Methodist Hospital-Sarah Cannon
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- University of Utah-Huntsman Cancer Institute
-
-
-
-
-
Hamburg, Tyskland, D-20246
- University Hospital Hamburg-Eppendorf
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. Subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this LTFU study. This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.
Beskrivelse
Inclusion Criteria:
- Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document.
- Must have received CRISPR CAR T cellular therapy.
Exclusion Criteria:
- There are no specific exclusion criteria.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Non Interventional
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. |
Safety and Efficacy Assessment |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment.
Tidsramme: 15 years
|
The number and percentage of subjects with CRISPR CAR T cellular therapy related SAEs and AESIs will be summarized. |
15 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The overall survival and duration of remission/response following CRISPR CAR T cellular therapy treatment
Tidsramme: 15 years
|
Overall survival will be calculated as the time between the initial dose of CRISPR CAR T cellular therapy in the parent study and death due to any cause. Duration of remission/response will be calculated as the time between the first objective response to first disease progression or death due to any cause. |
15 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CRSP-ONC-LTF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .